Recent Updates
Recently added Catalysts
LAB Positive Sentiment Score: 70/100

Standard BioTools to Present at 43rd Annual Cowen Health Care Conference

Key Takeaway: Standard BioTools Inc. will present at the Cowen Health Care Conference on March 8, 2023. The presentation will be led by the company's President and CEO, Michael Egholm, and will be available via live webcast. Standard BioTools, formerly known as Fluidigm Corporation, focuses on developing technologies that enhance biomedical research and improve patient outcomes. The company collaborates with various entities in the research and clinical sectors globally.

Market Sentiment Analysis

POSITIVE FACTORS

  • Standard BioTools is presenting at a major healthcare conference, demonstrating industry engagement.
  • The company's tools are designed to accelerate breakthroughs in human health, indicating a strong purpose.
  • Standard BioTools has an established portfolio of essential technologies that support biomedical research.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will present at the Cowen Health Care Conference on Wednesday, March 8, 2023, at 12:50 p.m. ET.
The presentation will be webcast live and available on the Investor Relations page of the company’s website at Events & Presentations. A recording of the webcast will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn®, and YouTube®. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo and “Unleashing tools to accelerate breakthroughs in human health” are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Scott R. Greenstone, CFA

Frequently Asked Questions

What is the purpose of Standard BioTools Inc.?

Standard BioTools Inc. aims to develop tools that accelerate breakthroughs in human health.

When will Michael Egholm present at the Cowen Health Care Conference?

Michael Egholm's presentation is scheduled for March 8, 2023, at 12:50 p.m. ET.

How can I access the Cowen Conference presentation webcast?

The presentation will be available live on the Investor Relations page of Standard BioTools' website.

What technologies does Standard BioTools utilize?

Standard BioTools employs mass cytometry and microfluidics technologies for biomedical research.

In which fields does Standard BioTools focus its research?

The company focuses on oncology, immunology, and immunotherapy in translational research.

Last updated: Mar 1, 2023